Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion Jennifer I. Lim , Adam R. Glassman , Lloyd Paul Aiello , Usha Chakravarthy , Christina J. Flaxel , Lawrence J. Singerman , Richard F. Spaide , Lloyd Paul Aiello , Jorge G. Arroyo , Sophie J. Bakri , Charlie C. Barr , Caroline R. Baumal , Kevin J. Blinder , Nauman A Chaudhry , Victor Chong , Albert O. Edwards , Allan Hunter , Michael J. Elman , Michel Eid Farah , Gary E. Fish , Alfonso Giovannini , Frank G. Holz , Rahul N. Khurana , Gregg T. Kokame , H. Richard McDonald , Stephan Michels , Roger L. Novack , Maurizio Battaglia Parodi , Carl D. Regillo , Kent W. Small , Fadi Shaya , Rickard F. Spaide , Giovani Staurenghi , Jennifer K. Sun , Demetrios G. Vavvas , Charles C. Wykoff , Lucy H. Young Ophthalmology Retina（2017）
摘要
Physician-reported outcomes on ocriplasmin use confirmed VMA release in 45% and closure of MH in 40% of eyes without PPVx. Visual acuity decreased in approximately 20% of eyes. Adverse events were not infrequent and suggest caution when considering ocriplasmin use.
更多 查看译文
关键词
CI, ERG, IRB, MH, PPVx, VMA, VMT
AI 理解论文
溯源树
样例
